Re-engineering therapeutic antibodies for Alzheimer's disease as blood-brain barrier penetrating bi-specific antibodies.

@article{Pardridge2016ReengineeringTA,
  title={Re-engineering therapeutic antibodies for Alzheimer's disease as blood-brain barrier penetrating bi-specific antibodies.},
  author={William M Pardridge},
  journal={Expert opinion on biological therapy},
  year={2016},
  volume={16 12},
  pages={1455-1468}
}
INTRODUCTION Therapeutic antibodies are large molecule drugs that do not cross the blood-brain barrier (BBB). Therefore, drug development of therapeutic antibodies for Alzheimer's disease (AD) requires that these molecules be re-engineered to enable BBB delivery. This is possible by joining the therapeutic antibody with a transporter antibody, resulting in… CONTINUE READING